Latest News for: entry inhibitor

Edit

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor

Hastings Tribune 06 Aug 2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – ... .
Edit

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ...

Nasdaq Globe Newswire 06 Aug 2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – ... .
Edit

New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation ...

Nasdaq Globe Newswire 07 May 2025
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – ... .
  • 1

Article Search

tools
×
×
×
×